A Study of Fluconazole in the Prevention of Fungal Infections in HIV-Infected Patients Living in Areas Where Fungal Infections Are Common

Sponsor
Pfizer (Industry)
Overall Status
Completed
CT.gov ID
NCT00002325
Collaborator
(none)
3

Study Details

Study Description

Brief Summary

To compare the efficacy of fluconazole versus placebo in preventing the development of active coccidioidomycosis and other systemic fungal infections among HIV-infected patients with CD4 lymphocyte counts < 250 cells/mm3 who are living in the coccidioidal endemic area.

Condition or Disease Intervention/Treatment Phase
N/A

Detailed Description

Patients are randomized to receive either fluconazole or placebo daily.

Study Design

Study Type:
Interventional
Intervention Model:
Parallel Assignment
Primary Purpose:
Treatment
Official Title:
A Double-Blind, Placebo-Controlled Study of Fluconazole in the Prevention of Active Coccidioidomycosis and Other Systemic Fungal Infections in HIV-Infected Patients Living in the Coccidioidal Endemic Area

Outcome Measures

Primary Outcome Measures

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    13 Years to 0 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No

    Inclusion Criteria

    Patients must have:
    • Documented HIV infection.

    • CD4 count < 250 cells/mm3.

    • No active coccidioidomycosis or other fungal disease requiring systemic antifungal therapy.

    • Residence in area considered to be endemic for Coccidioides immitis.

    • Consent of parent or guardian if under legal age of consent.

    Exclusion Criteria

    Co-existing Condition:
    Patients with the following symptoms or conditions are excluded:
    • Unable to take oral medication.

    • Positive serum cryptococcal antigen.

    Concurrent Medication:
    Excluded:
    • Systemic antifungal therapy.
    Patients with the following prior conditions are excluded:

    History of hypersensitivity to azole or imidazole compounds.

    Prior Medication:
    Excluded:
    • Systemic antifungal agents within 2 weeks prior to study entry.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 McDowell Clinic Phoenix Arizona United States 85006
    2 Tucson Veterans Administration Med Ctr Tucson Arizona United States 85723
    3 Dr Lawrence Cone Rancho Mirage California United States 92270

    Sponsors and Collaborators

    • Pfizer

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    , ,
    ClinicalTrials.gov Identifier:
    NCT00002325
    Other Study ID Numbers:
    • 012R
    • R-0266
    First Posted:
    Aug 31, 2001
    Last Update Posted:
    Jun 24, 2005
    Last Verified:
    Apr 1, 1996

    Study Results

    No Results Posted as of Jun 24, 2005